Medication Prescribed For Diabetics Could Help Osteoporosis

A

drug commonly prescribed to diabetics could make bones thinner and more fragile. The discovery could explain why diabetics are at increased osteoporisis risk of fractures.

New research suggests that treating diabetes long-term basis Rosiglitazone, sold under the brand name Avandia, is likely to lead to osteoporosis. The diabetes is used to stimulate response to insulin.

Some American researchers have discovered in laboratory mice, that the drug speeds up the activity of cells that cause bone loss, said a report released online at the website of Nature Medicine.

Avandia has recently been cautioned about the risk of heart failure in some patients. GlaxoSmithKline, which markets the drug, has already acknowledged that a study had found an increased osteoporosis risk of fracture in women taking the drug. But the latest report is the first to attempt to explain the relationship between diabetes and fractures.

This discovery will better understand the challenges associated with long-term treatment of patients with type 2 diabetes, and guide the development of a "new generation" of drugs to eliminate this side effect, according to the authors of the report .

The research was funded by the Howard Hughes Medical Institute and the National Institutes of Health.



Related Post :
Some Osteoporosis Statistics
67% of Quebecers do not consider themselves personally at developing osteoporosis risk
Osteoporosis Risk Test
If you answered yes to any of these osteoporosis risk questions, you are more likely to be suffering from osteoporosis. Consult a doctor and to measure your ...
Is It Prevents Osteoporosis ?
Learn how your lifestyle can prevent loss of bone mass and reduce your osteoporosis risk of suffering painful fractures. Bone is living tissue
Osteoporosis Prevention Childhood by Calcium
Insufficient calcium intake in childhood increases the osteoporosis risk factor in adulthood, according to a report by the Academy published Monday in the
Osteoporosis Diet: Citrus, Olives And… Phyto-estrogens On Menu
If the role of calcium and vitamin D is more to demonstrate in osteoporosis prevention

An Osteoporosis Medication Is Effective In Preventing Breast Cancer

A

n osteoporosis drug used to treat osteoporosis has halved the risk of developing breast cancer in patients predisposed to develop the disease.

These new and surprising results were revealed by a study conducted by the U.S. government on a sample of 20,000 women.

The study found that the "Raloxifen", currently marketed for osteoporosis treatment, has the same pharmacological properties as "Tamoxifen" in the prevention of breast cancer among women of advanced age and prone to develop, but causes minor side effects, said the National Cancer Institute.

The new results show that Raloxifen can replace tamoxifen as the first option for preventing breast cancer among menopausal women with a high risk of developing the disease, said the institute.

The Tamoxifen is so far the only drug approved to reduce the possibilities that breast cancer affects women more prone to disease.

The two drugs are selective modulators in response to estrogen. " They act like the hormone estrogen in some tissues but as an anti-estrogen in others.

The Tamoxifen can be administered to life, although it caused few serious effects, like increasing the risk of cancer of the uterus or generate potentially fatal obstructions in the circulatory system.

The Raloxifen may cause the same effects, but not so, according to the study by the National Cancer Institute with an investment of 88 million.